The presence of obesity, type 2 diabetes, and elevated systolic blood pressure (SBP) in adolescence accelerates the progression of risk factors that play a role in the development of early vascular aging.
Treatment of patients with hypertension who are infected with the severe acute respiratory syndrome coronavirus 2 with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers may improve clinical outcomes.
The Food and Drug Administration approved the 50cc temporary Total Artificial Heart System developed and manufactured by SynCardia Systems, LLC as a bridge to heart transplant for patients who are at imminent risk for death from biventricular failure.
Patients with cardiovascular disease diagnosed with novel coronavirus (COVID-19) are urged to continue taking their angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) medications as prescribed.
Pharmacologic cardioversion followed by electrical cardioversion and electrical cardioversion only were found to be safe and effective in patients presenting to the emergency department with recent onset acute atrial fibrillation.